Drugs that contain Calcifediol

1. List of Rayaldee drug patents

RAYALDEE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943530 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Feb, 2027

(3 years from now)

US8906410 EIRGEN Oral dosage form of 25-hydroxyvitamin D
Feb, 2027

(3 years from now)

US10213442 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Feb, 2027

(3 years from now)

US9925147 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(5 years from now)

US11154509 EIRGEN Methods for controlled release oral dosage of a vitamin D compound
Apr, 2028

(5 years from now)

US9498486 EIRGEN Method for controlled release oral dosage of a vitamin D compound
Apr, 2028

(5 years from now)

US8207149 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(5 years from now)

US8778373 EIRGEN Methods for controlled release oral dosage of a vitamin D compound
Apr, 2028

(5 years from now)

US9408858 EIRGEN Method for treating secondary hyperparathyroidism in CKD
Apr, 2028

(5 years from now)

US8361488 EIRGEN Methods and compositions for controlled release oral dosage of a vitamin D compound
Jul, 2028

(5 years from now)

US8426391 EIRGEN Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Aug, 2028

(5 years from now)

US11253528 EIRGEN Stabilized modified release Vitamin D formulation and method of administering same
Mar, 2034

(10 years from now)

US10357502 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(10 years from now)

US9861644 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(10 years from now)

US10300078 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(10 years from now)

Market Authorisation Date: 17 June, 2016

Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treating secondary hyperparathyroidism in ckd with sustained release calcifediol...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

RAYALDEE family patents

28

United States

12

European Union

10

Korea, Republic of

10

Japan

9

Hong Kong

8

Denmark

8

Portugal

8

Spain

7

Slovenia

7

Poland

5

Lithuania

5

Hungary

5

Canada

4

China

3

Croatia

3

Cyprus

3

RS

2

Israel

2

Australia

2

Philippines

2

Norway

2

Singapore

EA

2

EA

1

Mexico

1

Saudi Arabia

1

Costa Rica

1

Germany

1

Argentina

1

Brazil

1

Malaysia

1

Peru

1

Chile

1

Taiwan, Province of China

1

Ukraine

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in